On October 1st, The Royal Statistical Society (RSS) and Statisticians in the Pharmaceutical Industry Ltd (PSI) began to discuss formally whether a union of the two associations could benefit both societies.
RSS and PSI share many goals and activities. Discussions will evaluate whether the two societies could improve upon the delivery of those goals and activities without altering the character of either society to the detriment of their members, and will take place among a joint assessment committee (JAC) with appointees from both societies. The committee will meet formally in October, December and February. If discussions do identify a model for a union that the JAC believe will benefit both societies, each society will assess this model for the value it brings to its own members.
For PSI, this means an assessment by the BoD and by the members, most likely at an Annual General Meeting. A meeting of members (by teleconference) will be scheduled to allow PSI members to ask questions of the PSI representatives on the JAC, and to give their views on a union. The date of this meeting has yet to be set but will most likely take place in early January 2016, allowing members to hear the results of early discussions and give input into any proposed model of union. Further details will be communicated via eNews.
Please direct comments or questions to the PSI Chair, Mark Morris (mmorris@conatuspharma.com) or the PSI Secretariat (psi@mci-group.com).
This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
We have exciting new opportunities available for Study Statisticians, Support Statisticians and Exploratory Statisticians at various levels.
